NCT00143273 - Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation | Biotech Hunter

Enrollment

497

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Osteoporosis

Interventions

DRUG

lasofoxifene

0.05 mg tablets

DRUG

Placebo

0 mg

DRUG

Lasofoxifene

0.25 mg tablets

DRUG

Lasofoxifene

0.5 mg tablets

Trial Locations (17)

100

Pfizer Investigational Site, Taipei

810-0021

Pfizer Investigational Site, Fukuoka

892-0824

Pfizer Investigational Site, Kagoshima

892-0845

Pfizer Investigational Site, Kagoshima

880-0052

Pfizer Investigational Site, Miyazaki

183-0051

Pfizer Investigational Site, Fuchū

204-0021

Pfizer Investigational Site, Kiyose

106-0032

Pfizer Investigational Site, Minato-ku

108-0075

Pfizer Investigational Site, Minato-ku

157-0066

Pfizer Investigational Site, Setagaya-ku

683-8504

Pfizer Investigational Site, Yonago-shi

135-710

Pfizer Investigational Site, Kangnam-ku

138-736

Pfizer Investigational Site, Sonpagu

150-713

Pfizer Investigational Site, Youngdeungpo-gu

Unknown

Pfizer Investigational Site, Changhua

Pfizer Investigational Site, Taoyun 333

Pfizer Investigational Site